Completed NA INTERVENTIONAL 2-arm NCT00745589

Sevelamer Hydrochloride in Peritoneal Dialysis Patients (SERENE)

Use of Sevelamer Hydrochloride to Control Hyperphosphatemia and Reduce Calcification Burden in the Poor Peritoneal Dialysis Patients

Sponsor: The University of Hong Kong

Conditions Endstage Renal Disease

Interventions sevelamer hydrochloride

Updated 7 times since 2017 Last updated: Jun 17, 2020 Started: Jul 31, 2008 Primary completion: Oct 31, 2014 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00745589, this NA trial focuses on Endstage Renal Disease and remains completed. Sponsored by The University of Hong Kong, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jul 2020 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Jul 2020 [monthly]

Completed NA

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The University of Hong Kong

Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, Hong Kong